研究报告 Research Report 石药集团 2025 年实现收入 260 亿元（同比-10%），其中成药收入 206 亿元（同比-13%），原料药收入 37 亿元（同比+2%），功能食 品及其他业务 18 亿元（同比+4%）。毛利率 63.1%（同比-6.9 个百 分点）；研发费用 58 亿元（同比+12%），销售费用 65 亿元（同 比-25%）。归母净利润 39 亿元（-10%）。 25 Mar 2026 石药集团 CSPC Pharmaceutical Group (1093 HK) 25 年业绩回顾：基本面出清，管线催化丰富；看好长效多肽平台潜力 FY25 Results Review: Fundamentals Cleared; Rich Pipeline Catalysts; Bullish on the Potential of the Long-Acting Peptide Platform [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现 ...

Core Viewpoint - The company has provided insights into its business performance and future plans during a recent investor conference, highlighting stable caffeine demand, growth in biopharmaceutical sales, and ongoing clinical developments in its product pipeline. Group 1: Caffeine Business - Global caffeine demand is expected to remain stable, with a decrease in caffeine prices in 2025, yet the company managed to maintain high revenue through increased sales [1][4] - Caffeine prices have stabilized since 2026, and the company will continue to monitor price trends [4] Group 2: Biopharmaceutical Business - 2025 marks the first full sales year for the products Enshuxing and Enyitan, with significant revenue growth anticipated [11] - The company expects that gross margin fluctuations in 2025 will not be indicative of future performance, as sales enter a normal phase [12] - The company is optimistic about the development of its biopharmaceutical business, supported by an expanding sales team and increased marketing efforts in 2026 [11] Group 3: Research and Development - The company plans to invest 1.036 billion yuan in R&D in 2025, with substantial investment continuing into 2026 [2][7] - Key products, including SYS6010, SYS6043, and SYS6002, are scheduled for data readouts at major academic conferences in the first half of 2026 [2][5] Group 4: Clinical Pipeline Updates - SYS6010 has entered Phase 3 clinical trials with multiple indications under accelerated development, including EGFR wild-type lung cancer [3][9] - SYS6002 is currently in Phase 3 clinical trials for cervical cancer, while SYS6043 and SYS6040 are in Phase 1 trials exploring multiple indications [3][9] - SYS6090 is focusing on late-stage solid tumors, with ongoing domestic trials and plans for international Phase 1 trials [10] Group 5: Market Position and Future Plans - The company submitted its main board listing application to the Hong Kong Stock Exchange in December 2025, and the process is ongoing [8] - Collaboration with AstraZeneca involves innovative peptide molecules currently in preclinical research, aimed at providing long-term treatment solutions for obesity and related issues [8]

| | | | □特定对象调研 □分析师会议 | | --- | --- | --- | --- | | 投 资 者 | 关 系 | 活 | □媒体采访 □业绩说明会 | | 动类别 | | | □新闻发布会 □路演活动 | | | | | □现场参观 √其他（线上电话会议） | | 参与单位名称 | | | 中信建投（主持）、中信里昂、中信证券、华泰证券、东吴 | | | | | 证券、海通国际、兴业证券、申万宏源、国泰海通、德银证 | | | | | 券、华福证券、国金证券、中邮证券、国投证券、前海开源、 | | | | | 国盛医药、东方证券、西部证券、汇丰医药、Jefferies、摩根 | | | | | 士丹利、UOBKH、银河国际、禾其投资、LAV 资管、HBM | | | | | 资管、华安基金、华泰保险、汇添富基金、泰康资产、中银 | | | | | 资管、红筹投资、大家资产、华夏久盈、高毅资产、浦银安 | | | | | 盛、施罗德投资管理（香港）、淡水泉、鹏扬资金、国泰基 | | | | | 金、人保资产、涌容（香港）资管、安联基金等证券机构及 | | | | | 投资者 | | 时间 | ...